INSM
$114.41+5.19%
as of close, Nov 6, 2026
☾ AH $114.41 +5.19%
Head-to-head:Compare with ALNY or any ticker →
INSM SEC filings (2026)
CIK 1104506 · Pharmaceutical Preparations (SIC 2834) · incorporated in VA · fiscal year ends in December
1,823 filings on EDGAR since 2000 · 37 annual, 86 quarterly, 364 current · financial statements · earnings
Latest 10-K
Feb 19, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Oct 29, 2026
quarter to Sep 30, 2026
Latest 8-K
Oct 29, 2026
Results of operations
Last earnings release
Oct 29, 2026
−$0.46 vs −$0.34 · ▲ 15.1%
Filings on file
1,823
since 2000, 1,014 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
- Oct 29EarningsEarnings release — EPS −$0.46 vs −$0.34 est. (−35.3%); revenue $524.4M (+268% y/y) 15.1%
- Oct 29ReportQuarterly report, Q3 2026 — revenue $524.4M (+268% y/y), net income −$100.3M, EPS −$0.46
- Oct 208-K8-K · Directors or officers; compensation; Regulation FD disclosure
- Oct 58-K8-K · Directors or officers; compensation; Regulation FD disclosure
September 2026
- Sep 9Insider saleBrennan David R (Director) sold 25,000 shares for $3.1M at $124.00
August 2026
- Aug 17Insider saleSHAROKY MELVIN MD (Director) sold 5,000 shares for $638K at $127.53
- Aug 10Insider saleAdsett Roger (Chief Operating Officer) sold 239,850 shares for $32.0M at $133.27
- Aug 6EarningsEarnings release — EPS −$0.52 vs −$0.69 est. (+24.6%); revenue $425.5M (+296% y/y) 33.9%
- Aug 6ReportQuarterly report, Q2 2026 — revenue $425.5M (+296% y/y), net income −$13.2M, EPS −$0.06
- Aug 6Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 27,173 shares for $3.5M at $127.00–$129.40 under a 10b5-1 plan
July 2026
- Jul 23Insider saleLewis William (Chair and CEO · Director) sold 10,700 shares for $1.1M at $105.62–$106.43 under a 10b5-1 plan
- Jul 168-K8-K · Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial HypertensionRegulation FD disclosure
- Jul 9Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.3M at $116.55–$118.52 under a 10b5-1 plan
- Jul 6Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 12,302 shares for $1.4M at $109.02–$110.60 under a 10b5-1 plan
June 2026
- Jun 25Insider saleLewis William (Chair and CEO · Director) sold 21,398 shares for $2.2M at $102.34–$106.27 under a 10b5-1 plan
- Jun 22Insider saleSmith Michael Alexander (Chief Legal Officer) sold 1,806 shares for $173K at $95.82 under a 10b5-1 plan
- Jun 8Insider saleLewis William (Chair and CEO · Director) sold 6,515 shares for $613K at $94.03 under a 10b5-1 plan
- Jun 5Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 1,858 shares for $193K at $103.78 under a 10b5-1 plan
- Jun 3Insider saleLewis William (Chair and CEO · Director) sold 7,605 shares for $778K at $102.27
- Jun 3Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 2,566 shares for $262K at $102.27 under a 10b5-1 plan
- Jun 3Insider saleBonstein Sara (Chief Financial Officer) sold 2,404 shares for $246K at $102.27
- Jun 3Insider saleAdsett Roger (Chief Operating Officer) sold 2,370 shares for $242K at $102.27
- Jun 3Insider saleSmith Michael Alexander (Chief Legal Officer) sold 2,159 shares for $221K at $102.27
May 2026
- May 22Insider saleSmith Michael Alexander (Chief Legal Officer) sold 6,149 shares for $667K at $108.47 under a 10b5-1 plan
- May 18Insider saleLewis William (Chair and CEO · Director) sold 25,564 shares for $2.7M at $105.32–$106.97 under a 10b5-1 plan
- May 158-K8-K · Shareholder vote results
- May 14Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 10,479 shares for $1.2M at $117.54 under a 10b5-1 plan
- May 13Insider saleLewis William (Chair and CEO · Director) sold 13,283 shares for $1.5M at $116.18
- May 13Insider saleBonstein Sara (Chief Financial Officer) sold 8,272 shares for $961K at $116.18
- May 13Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 7,854 shares for $897K at $112.76–$116.18 under a 10b5-1 plan
- May 13Insider saleAdsett Roger (Chief Operating Officer) sold 5,837 shares for $678K at $116.18
- May 13Insider saleSmith Michael Alexander (Chief Legal Officer) sold 4,109 shares for $477K at $116.18
- May 11Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 12,949 shares for $1.3M at $100.35–$101.18 under a 10b5-1 plan
- May 7EarningsEarnings release — EPS −$0.76 vs −$0.90 est. (+15.6%); revenue $306.0M (+230% y/y) 23.4%
- May 7ReportQuarterly report, Q1 2026 — revenue $306.0M (+230% y/y), net income −$163.6M, EPS −$0.76
- May 4Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.5M at $134.18–$139.60 under a 10b5-1 plan
April 2026
- Apr 16Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.5M at $142.99–$145.79 under a 10b5-1 plan
- Apr 78-K8-K · Regulation FD disclosure; Other events
- Apr 6Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.7M at $161.73–$164.01 under a 10b5-1 plan
- Apr 1Insider saleAdsett Roger (Chief Operating Officer) sold 88,060 shares for $14.5M at $163.18–$164.95 under a 10b5-1 plan
- Apr 1ProxyProxy · Annual report to shareholders
- Apr 1ProxyProxy · Additional proxy materials
- Apr 1ProxyProxy · Proxy statement
March 2026
- Mar 30Insider saleSmith Michael Alexander (Chief Legal Officer) sold 19,638 shares for $3.0M at $150.98 under a 10b5-1 plan
- Mar 238-K8-K · Regulation FD disclosure; Other events
- Mar 19Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.5M at $142.17–$144.11 under a 10b5-1 plan
- Mar 5Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.6M at $144.23–$147.54 under a 10b5-1 plan
February 2026
- Feb 24Insider saleSmith Michael Alexander (Chief Legal Officer) sold 24,774 shares for $3.9M at $153.93–$156.53 under a 10b5-1 plan
- Feb 19EarningsEarnings release — EPS −$1.54 vs −$1.07 est. (−43.9%); revenue $263.8M (+153% y/y) 6.5%
- Feb 19ReportAnnual report, FY2025 — revenue $606.4M (+67% y/y), net income −$1.28B, EPS −$6.42
- Feb 19Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.6M at $149.17–$153.38 under a 10b5-1 plan
- Feb 9Insider saleLewis William (Chair and CEO · Director) sold 13,396 shares for $2.0M at $147.17–$148.83 under a 10b5-1 plan
- Feb 5Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 869 shares for $132K at $152.44 under a 10b5-1 plan
- Feb 3Insider saleLewis William (Chair and CEO · Director) sold 3,009 shares for $470K at $156.34
- Feb 3Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 795 shares for $124K at $155.77 under a 10b5-1 plan
- Feb 3Insider saleAdsett Roger (Chief Operating Officer) sold 791 shares for $124K at $156.17
- Feb 3Insider saleBonstein Sara (Chief Financial Officer) sold 748 shares for $117K at $156.34
- Feb 3Insider saleSmith Michael Alexander (Chief Legal Officer) sold 640 shares for $100K at $156.27
- Feb 2Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 7,982 shares for $1.2M at $152.06–$156.86 under a 10b5-1 plan
January 2026
- Jan 20Insider saleLewis William (Chair and CEO · Director) sold 10,699 shares for $1.7M at $156.80–$160.70 under a 10b5-1 plan
- Jan 12Insider saleLewis William (Chair and CEO · Director) sold 19,215 shares for $3.2M at $167.73–$174.86 under a 10b5-1 plan
- Jan 9Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 1,887 shares for $351K at $186.19 under a 10b5-1 plan
- Jan 98-K8-K · Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceRegulation FD disclosure
- Jan 8Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 4,911 shares for $855K at $173.87–$174.17 under a 10b5-1 plan
- Jan 8Insider saleLewis William (Chair and CEO · Director) sold 3,223 shares for $561K at $174.17
- Jan 8Insider saleAdsett Roger (Chief Operating Officer) sold 2,059 shares for $359K at $174.17
- Jan 8Insider saleBonstein Sara (Chief Financial Officer) sold 1,447 shares for $252K at $174.17
- Jan 8Insider saleSmith Michael Alexander (Chief Legal Officer) sold 1,053 shares for $183K at $174.17
- Jan 7Insider saleLewis William (Chair and CEO · Director) sold 2,357 shares for $413K at $175.07
- Jan 7Insider saleBonstein Sara (Chief Financial Officer) sold 1,678 shares for $294K at $175.07
- Jan 7Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 1,434 shares for $252K at $175.84 under a 10b5-1 plan
- Jan 7Insider saleAdsett Roger (Chief Operating Officer) sold 802 shares for $140K at $175.07
- Jan 7Insider saleSmith Michael Alexander (Chief Legal Officer) sold 709 shares for $124K at $175.07
- Jan 6Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 10,185 shares for $1.8M at $173.33–$175.01 under a 10b5-1 plan
- Jan 6Insider saleLewis William (Chair and CEO · Director) sold 4,096 shares for $710K at $173.33
- Jan 6Insider saleBonstein Sara (Chief Financial Officer) sold 1,517 shares for $263K at $173.33
- Jan 6Insider saleAdsett Roger (Chief Operating Officer) sold 1,429 shares for $248K at $173.33
- Jan 6Insider saleSmith Michael Alexander (Chief Legal Officer) sold 1,396 shares for $242K at $173.33
- Jan 5Insider saleFlammer Martina M.D. (Chief Medical Officer) sold 12,303 shares for $2.1M at $169.29–$175.73 under a 10b5-1 plan
- Jan 2Insider saleSchaeffer Orlov S Nicole (Chief People Strategy Officer) sold 87,290 shares for $15.3M at $174.28–$177.78 under a 10b5-1 plan
December 2025
- Dec 178-K8-K · Regulation FD disclosure; Other events
November 2025
- Nov 188-K8-K · Regulation FD disclosure; Other events
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $122.8M in 62 sales and bought nothing on the open market; 74 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 9, 2026Form 4 | Brennan David RDirectorSold · $3.1M · 25,000 sh |
| Aug 17, 2026Form 4 | SHAROKY MELVIN MDDirectorSold · $638K · 5,000 sh |
| Aug 10, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $32.0M · 239,850 sh |
| Aug 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $3.5M · 27,173 sh · 10b5-1 |
| Jul 23, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.1M · 10,700 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.3M · 10,699 sh · 10b5-1 |
| Jul 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $1.4M · 12,302 sh · 10b5-1 |
| Jun 25, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $2.2M · 21,398 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $173K · 1,806 sh · 10b5-1 |
| Jun 8, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $613K · 6,515 sh · 10b5-1 |
| Jun 5, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $193K · 1,858 sh · 10b5-1 |
| Jun 3, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $778K · 7,605 sh |
| Jun 3, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $262K · 2,566 sh · 10b5-1 |
| Jun 3, 2026Form 4 | Bonstein SaraChief Financial OfficerSold · $246K · 2,404 sh |
| Jun 3, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $242K · 2,370 sh |
| Jun 3, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $221K · 2,159 sh |
| May 22, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $667K · 6,149 sh · 10b5-1 |
| May 18, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $2.7M · 25,564 sh · 10b5-1 |
| May 14, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $1.2M · 10,479 sh · 10b5-1 |
| May 13, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.5M · 13,283 sh |
| May 13, 2026Form 4 | Bonstein SaraChief Financial OfficerSold · $961K · 8,272 sh |
| May 13, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $897K · 7,854 sh · 10b5-1 |
| May 13, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $678K · 5,837 sh |
| May 13, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $477K · 4,109 sh |
| May 11, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $1.3M · 12,949 sh · 10b5-1 |
| May 4, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.5M · 10,699 sh · 10b5-1 |
| Apr 16, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.5M · 10,699 sh · 10b5-1 |
| Apr 6, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.7M · 10,699 sh · 10b5-1 |
| Apr 1, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $14.5M · 88,060 sh · 10b5-1 |
| Mar 30, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $3.0M · 19,638 sh · 10b5-1 |
| Mar 19, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.5M · 10,699 sh · 10b5-1 |
| Mar 5, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.6M · 10,699 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $3.9M · 24,774 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.6M · 10,699 sh · 10b5-1 |
| Feb 9, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $2.0M · 13,396 sh · 10b5-1 |
| Feb 5, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $132K · 869 sh · 10b5-1 |
| Feb 3, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $470K · 3,009 sh |
| Feb 3, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $124K · 795 sh · 10b5-1 |
| Feb 3, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $124K · 791 sh |
| Feb 3, 2026Form 4 | Bonstein SaraChief Financial OfficerSold · $117K · 748 sh |
| Feb 3, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $100K · 640 sh |
| Feb 2, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $1.2M · 7,982 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $1.7M · 10,699 sh · 10b5-1 |
| Jan 12, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $3.2M · 19,215 sh · 10b5-1 |
| Jan 9, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $351K · 1,887 sh · 10b5-1 |
| Jan 8, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $855K · 4,911 sh · 10b5-1 |
| Jan 8, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $561K · 3,223 sh |
| Jan 8, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $359K · 2,059 sh |
| Jan 8, 2026Form 4 | Bonstein SaraChief Financial OfficerSold · $252K · 1,447 sh |
| Jan 8, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $183K · 1,053 sh |
| Jan 7, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $413K · 2,357 sh |
| Jan 7, 2026Form 4 | Bonstein SaraChief Financial OfficerSold · $294K · 1,678 sh |
| Jan 7, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $252K · 1,434 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $140K · 802 sh |
| Jan 7, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $124K · 709 sh |
| Jan 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $1.8M · 10,185 sh · 10b5-1 |
| Jan 6, 2026Form 4 | Lewis WilliamChair and CEO · DirectorSold · $710K · 4,096 sh |
| Jan 6, 2026Form 4 | Bonstein SaraChief Financial OfficerSold · $263K · 1,517 sh |
| Jan 6, 2026Form 4 | Adsett RogerChief Operating OfficerSold · $248K · 1,429 sh |
| Jan 6, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerSold · $242K · 1,396 sh |
| Jan 5, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerSold · $2.1M · 12,303 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Schaeffer Orlov S NicoleChief People Strategy OfficerSold · $15.3M · 87,290 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 74 transactions
| Date | Insider |
|---|---|
| Oct 19, 2026Form 4 | Koppikar UtpalDirectorAward · — · 6,139 sh |
| Oct 19, 2026Form 4 | Hudson PaulDirectorAward · — · 6,139 sh |
| Aug 10, 2026Form 4 | Adsett RogerChief Operating OfficerExercise or conversion · $4.9M · 239,850 sh |
| Aug 10, 2026Form 4 | Adsett RogerChief Operating OfficerExercise or conversion · Stock Option (right to buy) · $0 · 239,850 sh |
| Aug 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · $576K · 27,173 sh · 10b5-1 |
| Aug 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · Stock Option (right to buy) · $0 · 27,173 sh · 10b5-1 |
| Jul 23, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,700 sh · 10b5-1 |
| Jul 23, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,700 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Jul 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · $317K · 12,302 sh · 10b5-1 |
| Jul 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · Stock Option (right to buy) · $0 · 12,302 sh · 10b5-1 |
| Jun 25, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $534K · 21,398 sh · 10b5-1 |
| Jun 25, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 21,398 sh · 10b5-1 |
| Jun 23, 2026Form 4 | Butera SamueleSVP, GM, Global RespiratoryAward · Stock Option (right to buy) · $0 · 12,570 sh |
| Jun 23, 2026Form 4 | Butera SamueleSVP, GM, Global RespiratoryAward · — · 7,342 sh |
| May 18, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| May 18, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| May 13, 2026Form 4 | SHAROKY MELVIN MDDirectorAward · — · 3,305 sh |
| May 13, 2026Form 4 | SCHAFER CAROLDirectorAward · — · 3,305 sh |
| May 13, 2026Form 4 | Brennan David RDirectorAward · — · 3,305 sh |
| May 13, 2026Form 4 | LEE LEODirectorAward · — · 3,305 sh |
| May 13, 2026Form 4 | ANDERSON ELIZABETH MDirectorAward · — · 3,305 sh |
| May 13, 2026Form 4 | Desjardins ClarissaDirectorAward · — · 3,305 sh |
| May 11, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · $221K · 12,949 sh · 10b5-1 |
| May 11, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · Stock Option (right to buy) · $0 · 12,949 sh · 10b5-1 |
| May 4, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| May 4, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Apr 16, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Apr 16, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Apr 6, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Apr 6, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Apr 1, 2026Form 4 | Adsett RogerChief Operating OfficerExercise or conversion · $1.3M · 88,060 sh · 10b5-1 |
| Apr 1, 2026Form 4 | Adsett RogerChief Operating OfficerExercise or conversion · Stock Option (right to buy) · $0 · 88,060 sh · 10b5-1 |
| Mar 30, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerExercise or conversion · $487K · 19,638 sh · 10b5-1 |
| Mar 30, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerExercise or conversion · Stock Option (right to buy) · $0 · 19,638 sh · 10b5-1 |
| Mar 19, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Mar 19, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Mar 5, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Mar 5, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Mar 3, 2026Form 4 | SHAROKY MELVIN MDDirectorGift · $0 · 100 sh |
| Feb 25, 2026Form 4 | SHAROKY MELVIN MDDirectorGift · $0 · 2,044 sh |
| Feb 24, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerExercise or conversion · $346K · 20,248 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,248 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Brennan David RDirectorGift · $0 · 6,000 sh |
| Feb 19, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Feb 9, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Feb 9, 2026Form 4 | MCGIRR DAVID W JDirectorGift · $0 · 106,800 sh |
| Feb 9, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Feb 2, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · $525K · 7,982 sh · 10b5-1 |
| Feb 2, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · Stock Option (right to buy) · $0 · 7,982 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Jan 20, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Jan 12, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · $267K · 10,699 sh · 10b5-1 |
| Jan 12, 2026Form 4 | Lewis WilliamChair and CEO · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 10,699 sh · 10b5-1 |
| Jan 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · $227K · 8,570 sh · 10b5-1 |
| Jan 6, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · Stock Option (right to buy) · $0 · 8,570 sh · 10b5-1 |
| Jan 5, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · $317K · 12,303 sh · 10b5-1 |
| Jan 5, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerExercise or conversion · Stock Option (right to buy) · $0 · 12,303 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Schaeffer Orlov S NicoleChief People Strategy OfficerExercise or conversion · $1.2M · 87,290 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Lewis WilliamChair and CEO · DirectorAward · Stock Option (right to buy) · $0 · 110,400 sh |
| Jan 2, 2026Form 4 | Schaeffer Orlov S NicoleChief People Strategy OfficerExercise or conversion · Stock Option (right to buy) · $0 · 87,290 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Bonstein SaraChief Financial OfficerAward · Stock Option (right to buy) · $0 · 31,280 sh |
| Jan 2, 2026Form 4 | Adsett RogerChief Operating OfficerAward · Stock Option (right to buy) · $0 · 31,280 sh |
| Jan 2, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerAward · Stock Option (right to buy) · $0 · 31,280 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Schaeffer Orlov S NicoleChief People Strategy OfficerAward · Stock Option (right to buy) · $0 · 27,600 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerAward · Stock Option (right to buy) · $0 · 27,600 sh |
| Jan 2, 2026Form 4 | Lewis WilliamChair and CEO · DirectorAward · — · 21,172 sh |
| Jan 2, 2026Form 4 | Bonstein SaraChief Financial OfficerAward · — · 11,643 sh |
| Jan 2, 2026Form 4 | Flammer Martina M.D.Chief Medical OfficerAward · — · 11,643 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Adsett RogerChief Operating OfficerAward · — · 5,998 sh |
| Jan 2, 2026Form 4 | Schaeffer Orlov S NicoleChief People Strategy OfficerAward · — · 5,293 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Smith Michael AlexanderChief Legal OfficerAward · — · 5,293 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 18 filings
| Filed | What it is |
|---|---|
| Oct 29, 20268-K | Earnings release — EPS −$0.46 vs −$0.34 est. (−35.3%); revenue $524.4M (+268% y/y) 15.1% |
| Oct 29, 202610-Q | Quarterly report, Q3 2026 — revenue $524.4M (+268% y/y), net income −$100.3M, EPS −$0.46 |
| Oct 20, 20268-K | Directors or officers; compensation; Regulation FD disclosure |
| Oct 5, 20268-K | Directors or officers; compensation; Regulation FD disclosure |
| Aug 6, 20268-K | Earnings release — EPS −$0.52 vs −$0.69 est. (+24.6%); revenue $425.5M (+296% y/y) 33.9% |
| Aug 6, 202610-Q | Quarterly report, Q2 2026 — revenue $425.5M (+296% y/y), net income −$13.2M, EPS −$0.06 |
| Jul 16, 20268-K | Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial HypertensionRegulation FD disclosure |
| May 15, 20268-K | Shareholder vote results |
| May 7, 20268-K | Earnings release — EPS −$0.76 vs −$0.90 est. (+15.6%); revenue $306.0M (+230% y/y) 23.4% |
| May 7, 202610-Q | Quarterly report, Q1 2026 — revenue $306.0M (+230% y/y), net income −$163.6M, EPS −$0.76 |
| Apr 7, 20268-K | Regulation FD disclosure; Other events |
| Apr 1, 2026ARS | Annual report to shareholders |
| Apr 1, 2026DEFA14A | Additional proxy materials |
| Apr 1, 2026DEF 14A | Proxy statement |
| Mar 23, 20268-K | Regulation FD disclosure; Other events |
| Feb 19, 202610-K | Annual report, FY2025 — revenue $606.4M (+67% y/y), net income −$1.28B, EPS −$6.42 |
| Feb 19, 20268-K | Earnings release — EPS −$1.54 vs −$1.07 est. (−43.9%); revenue $263.8M (+153% y/y) 6.5% |
| Jan 9, 20268-K | Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceRegulation FD disclosure |
2025 · 24 filings
| Filed | What it is |
|---|---|
| Dec 17, 20258-K | Regulation FD disclosure; Other events |
| Nov 18, 20258-K | Regulation FD disclosure; Other events |
| Oct 30, 202510-Q | Quarterly report, Q3 2025 — revenue $142.3M (+52% y/y), net income −$370.0M, EPS −$1.75 |
| Oct 30, 20258-K | Earnings release — EPS −$1.75 vs −$1.32 est. (−32.6%); revenue $142.3M (+52% y/y) 16.3% |
| Aug 12, 20258-K | Regulation FD disclosure; Other events |
| Aug 7, 20258-K | Earnings release — EPS −$1.70 vs −$1.30 est. (−30.8%); revenue $107.4M (+19% y/y) 1.8% |
| Aug 7, 202510-Q | Quarterly report, Q2 2025 — revenue $107.4M (+19% y/y), net income −$321.7M, EPS −$1.70 |
| Jun 13, 20258-K | Regulation FD disclosure; Other events |
| Jun 10, 20258-K | Regulation FD disclosure; Other events |
| Jun 6, 20258-K | Other events |
| May 16, 20258-K | Directors or officers; compensation; Shareholder vote results |
| May 8, 20258-K | Earnings release — EPS −$1.42 vs −$1.36 est. (−4.4%); revenue $92.8M (+23% y/y) 3.9% |
| May 8, 202510-Q | Quarterly report, Q1 2025 — revenue $92.8M (+23% y/y), net income −$256.6M, EPS −$1.42 |
| Apr 24, 20258-K/A | Other events |
| Apr 24, 20258-K | Other events |
| Apr 17, 20258-K | Directors or officers; compensation |
| Apr 4, 2025ARS | Annual report to shareholders |
| Apr 4, 2025DEFA14A | Additional proxy materials |
| Apr 4, 2025DEF 14A | Proxy statement |
| Feb 24, 20258-K | Regulation FD disclosure; Other events |
| Feb 20, 20258-K | Earnings release — EPS −$1.32 vs −$1.15 est. (−14.8%); revenue $104.4M (+25% y/y) 0.3% |
| Feb 20, 202510-K | Annual report, FY2024 — revenue $363.7M (+19% y/y), net income −$913.8M, EPS −$5.57 |
| Feb 6, 20258-K | Regulation FD disclosure; Other events |
| Jan 10, 20258-K | Regulation FD disclosure |
2024 · 21 filings
| Filed | What it is |
|---|---|
| Nov 19, 20248-K | Termination of a material agreement |
| Oct 31, 20248-K | Earnings release — EPS −$1.27 vs −$1.19 est. (−6.7%); revenue $93.4M (+18% y/y) 4.3% |
| Oct 31, 202410-Q | Quarterly report, Q3 2024 — revenue $93.4M (+18% y/y), net income −$220.5M, EPS −$1.27 |
| Aug 9, 20248-K | Other events |
| Aug 8, 20248-K | Earnings release — EPS −$1.94 vs −$1.22 est. (−59.0%); revenue $90.3M (+17% y/y) 1.2% |
| Aug 8, 202410-Q | Quarterly report, Q2 2024 — revenue $90.3M (+17% y/y), net income −$300.6M, EPS −$1.94 |
| Jul 3, 20248-K | Regulation FD disclosure |
| Jun 27, 20248-K | Other events |
| Jun 13, 20248-K | Other events |
| Jun 4, 20248-K | Regulation FD disclosure |
| May 30, 20248-K | Regulation FD disclosure; Other events |
| May 28, 20248-K | Regulation FD disclosure; Other events |
| May 13, 20248-K | Directors or officers; compensation; Shareholder vote results |
| May 9, 20248-K | Earnings release — EPS −$1.06 vs −$1.22 est. (+13.1%); revenue $75.5M (+16% y/y) 1.5% |
| May 9, 202410-Q | Quarterly report, Q1 2024 — revenue $75.5M (+16% y/y), net income −$157.1M, EPS −$1.06 |
| Apr 1, 2024DEFA14A | Additional proxy materials |
| Apr 1, 2024DEF 14A | Proxy statement |
| Mar 11, 20248-K | Other events |
| Feb 22, 20248-K | Earnings release — EPS −$1.28 vs −$1.13 est. (−13.3%); revenue $83.7M (+41% y/y) 3.9% |
| Feb 22, 202410-K | Annual report, FY2023 — revenue $305.2M (+24% y/y), net income −$749.6M, EPS −$5.34 |
| Jan 5, 20248-K | Regulation FD disclosure |
2023 · 15 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 26, 202310-Q | Quarterly report, Q3 2023 — revenue $79.1M (+17% y/y), net income −$158.9M, EPS −$1.11 |
| Aug 3, 202310-Q | Quarterly report, Q2 2023 — revenue $77.2M (+18% y/y), net income −$244.8M, EPS −$1.78 |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $65.2M (+23% y/y), net income −$159.8M, EPS −$1.17 |
| Mar 31, 2023DEFA14A | Additional proxy materials |
| Mar 31, 2023DEF 14A | Proxy statement |
| Feb 23, 202310-K | Annual report, FY2022 — revenue $245.4M (+30% y/y), net income −$481.5M, EPS −$3.91 |
9 current reports (8-K) not listed; the year is on EDGAR.
2022 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 27, 202210-Q | Quarterly report, Q3 2022 — revenue $67.7M (+45% y/y), net income −$131.1M, EPS −$1.09 |
| Aug 4, 202210-Q | Quarterly report, Q2 2022 — revenue $65.2M (+44% y/y), net income −$95.6M, EPS −$0.80 |
| May 5, 202210-Q | Quarterly report, Q1 2022 — revenue $53.1M (+32% y/y), net income −$94.6M, EPS −$0.80 |
| Apr 1, 2022DEFA14A | Additional proxy materials |
| Apr 1, 2022DEF 14A | Proxy statement |
| Feb 17, 202210-K | Annual report, FY2021 — revenue $188.5M (+15% y/y), net income −$434.7M, EPS −$3.88 |
9 current reports (8-K) not listed; the year is on EDGAR.
2021 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 28, 202110-Q | Quarterly report, Q3 2021 — revenue $46.8M (+7% y/y), net income −$112.7M, EPS −$0.96 |
| Aug 5, 202110-Q | Quarterly report, Q2 2021 — revenue $45.4M (+7% y/y), net income −$117.3M, EPS −$1.07 |
| May 6, 202110-Q | Quarterly report, Q1 2021 — revenue $40.2M (+9% y/y), net income −$91.6M, EPS −$0.89 |
| Apr 1, 2021DEFA14A | Additional proxy materials |
| Apr 1, 2021DEF 14A | Proxy statement |
| Feb 25, 202110-K | Annual report, FY2020 — revenue $164.4M (+20% y/y), net income −$294.1M, EPS −$3.01 |
10 current reports (8-K) not listed; the year is on EDGAR.
2020 · 23 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 29, 202010-Q | Quarterly report, Q3 2020 — revenue $43.6M (+12% y/y), net income −$63.7M, EPS −$0.63 |
| Aug 6, 202010-Q | Quarterly report, Q2 2020 — revenue $42.5M (+42% y/y), net income −$61.9M, EPS −$0.64 |
| Apr 30, 202010-Q | Quarterly report, Q1 2020 — revenue $36.9M (+68% y/y), net income −$66.4M |
| Mar 31, 2020DEFA14A | Additional proxy materials |
| Mar 31, 2020DEF 14A | Proxy statement |
| Feb 25, 202010-K | Annual report, FY2019 — revenue $136.5M (+1288% y/y), net income −$254.3M, EPS −$3.01 |
17 current reports (8-K) not listed; the year is on EDGAR.
2019 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 30, 201910-Q | Quarterly report, Q3 2019 — revenue $38.9M, net income −$60.7M |
| Aug 1, 201910-Q | Quarterly report, Q2 2019 — revenue $30.0M, net income −$66.5M |
| May 7, 201910-Q | Quarterly report, Q1 2019 — revenue $21.9M, net income −$74.2M |
| Apr 4, 2019DEFA14A | Additional proxy materials |
| Apr 4, 2019DEF 14A | Proxy statement |
| Feb 22, 201910-K | Annual report, FY2018 — revenue $9.8M, net income −$324.3M |
13 current reports (8-K) not listed; the year is on EDGAR.
2018 · 20 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 30, 201810-Q | Quarterly report, Q3 2018 — revenue $0, net income −$87.7M |
| Aug 2, 201810-Q | Quarterly report, Q2 2018 — revenue $0, net income −$76.4M |
| May 2, 201810-Q | Quarterly report, Q1 2018 — revenue $0, net income −$68.5M |
| Apr 5, 2018DEFA14A | Additional proxy materials |
| Apr 5, 2018DEF 14A | Proxy statement |
| Feb 23, 201810-K | Annual report, FY2017 — revenue $0, net income −$192.6M |
14 current reports (8-K) not listed; the year is on EDGAR.
2017 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 2, 201710-Q | Quarterly report, Q3 2017 — revenue $0, net income −$45.2M |
| Aug 3, 201710-Q | Quarterly report, Q2 2017 — revenue $0, net income −$44.7M |
| May 3, 201710-Q | Quarterly report, Q1 2017 — revenue $0, net income −$37.4M |
| Apr 7, 2017DEFA14A | Additional proxy materials |
| Apr 7, 2017DEF 14A | Proxy statement |
| Feb 23, 201710-K | Annual report, FY2016 — revenue $0, net income −$176.3M |
10 current reports (8-K) not listed; the year is on EDGAR.
2016 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2015 · 18 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2014 · 28 filings — 21 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2013 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2012 · 36 filings — 31 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2011 · 37 filings — 25 × 8-K, 4 × DEF 14A, 3 × 10-Q and 5 other forms
Counted, not listed; the year is on EDGAR.
2010 · 19 filings — 11 × 8-K, 3 × 10-Q, 3 × DEF 14A and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 21 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2008 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2007 · 22 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2006 · 32 filings — 18 × 8-K, 3 × 10-K/A, 3 × 10-Q and 4 other forms
Counted, not listed; the year is on EDGAR.
2005 · 31 filings — 21 × 8-K, 4 × 10-K/A, 3 × 10-Q and 3 other forms
Counted, not listed; the year is on EDGAR.
2004 · 15 filings — 7 × 8-K, 3 × 10-Q, 2 × 10-K/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2003 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2002 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K405 and 1 other form
Counted, not listed; the year is on EDGAR.
2001 · 10 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2000 · 9 filings — 5 × 8-K, 3 × 10-Q, 1 × 8-K/A
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 142 filings — 66 × 4, 63 × 144, 6 × SCHEDULE 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Nov 3, 2026144 | Notice of proposed sale (Form 144) |
| Nov 3, 20263 | Initial insider holdings (Form 3) |
| Oct 20, 20264 | Insider transaction (Form 4) |
| Oct 20, 20264 | Insider transaction (Form 4) |
| Oct 20, 20263 | Initial insider holdings (Form 3) |
| Oct 20, 20263 | Initial insider holdings (Form 3) |
| Sep 11, 20264 | Insider transaction (Form 4) |
| Sep 10, 2026144 | Notice of proposed sale (Form 144) |
| Aug 19, 20264 | Insider transaction (Form 4) |
| Aug 17, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 2026SCHEDULE 13G/A | Other filings |
| Aug 12, 20264 | Insider transaction (Form 4) |
| Aug 10, 2026144 | Notice of proposed sale (Form 144) |
| Aug 7, 20264 | Insider transaction (Form 4) |
| Aug 6, 2026144 | Notice of proposed sale (Form 144) |
| Aug 6, 2026SCHEDULE 13G/A | Other filings |
| Jul 24, 20264 | Insider transaction (Form 4) |
| Jul 23, 2026144 | Notice of proposed sale (Form 144) |
| Jul 22, 2026SCHEDULE 13G/A | Other filings |
| Jul 10, 20264 | Insider transaction (Form 4) |
| Jul 9, 2026144 | Notice of proposed sale (Form 144) |
| Jul 8, 20264 | Insider transaction (Form 4) |
| Jul 6, 2026144 | Notice of proposed sale (Form 144) |
| Jun 26, 20264 | Insider transaction (Form 4) |
| Jun 25, 2026144 | Notice of proposed sale (Form 144) |
The newest 25 of 142 shown; the full year is on EDGAR.
2025 · 227 filings — 115 × 144, 99 × 4, 8 × SCHEDULE 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Dec 19, 20254 | Insider transaction (Form 4) |
| Dec 18, 2025144 | Notice of proposed sale (Form 144) |
| Dec 9, 20254 | Insider transaction (Form 4) |
| Dec 5, 2025144 | Notice of proposed sale (Form 144) |
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 4, 2025144 | Notice of proposed sale (Form 144) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Nov 26, 20254 | Insider transaction (Form 4) |
| Nov 24, 2025144 | Notice of proposed sale (Form 144) |
| Nov 18, 20254 | Insider transaction (Form 4) |
| Nov 18, 20254 | Insider transaction (Form 4) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 2025SCHEDULE 13G/A | Other filings |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 14, 2025SCHEDULE 13G/A | Other filings |
| Nov 13, 20254 | Insider transaction (Form 4) |
| Nov 13, 2025144 | Notice of proposed sale (Form 144) |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 10, 20254 | Insider transaction (Form 4) |
| Nov 5, 20254 | Insider transaction (Form 4) |
| Nov 3, 2025144 | Notice of proposed sale (Form 144) |
| Sep 15, 20254 | Insider transaction (Form 4) |
| Sep 15, 20254 | Insider transaction (Form 4) |
The newest 25 of 227 shown; the full year is on EDGAR.
2024 · 100 filings — 53 × 4, 35 × 144, 6 × SC 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 19, 2024144 | Notice of proposed sale (Form 144) |
| Dec 13, 20244 | Insider transaction (Form 4) |
| Dec 12, 2024144 | Notice of proposed sale (Form 144) |
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Sep 16, 20244 | Insider transaction (Form 4) |
| Sep 16, 20244 | Insider transaction (Form 4) |
| Sep 13, 2024144 | Notice of proposed sale (Form 144) |
| Sep 10, 20244 | Insider transaction (Form 4) |
| Sep 10, 2024144 | Notice of proposed sale (Form 144) |
| Sep 10, 20244 | Insider transaction (Form 4) |
| Sep 6, 2024144 | Notice of proposed sale (Form 144) |
| Sep 3, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Sep 3, 20244 | Insider transaction (Form 4) |
| Aug 22, 2024144 | Notice of proposed sale (Form 144) |
| Aug 14, 20244 | Insider transaction (Form 4) |
| Aug 14, 20244 | Insider transaction (Form 4) |
| Aug 12, 2024144 | Notice of proposed sale (Form 144) |
| Aug 12, 2024144 | Notice of proposed sale (Form 144) |
| Jul 10, 20244 | Insider transaction (Form 4) |
| Jun 12, 20244 | Insider transaction (Form 4) |
| Jun 5, 20244 | Insider transaction (Form 4) |
| Jun 3, 2024144 | Notice of proposed sale (Form 144) |
| May 30, 20244 | Insider transaction (Form 4) |
| May 30, 20244 | Insider transaction (Form 4) |
The newest 25 of 100 shown; the full year is on EDGAR.
2023 · 70 filings — 45 × 4, 14 × 144, 6 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2022 · 58 filings — 48 × 4, 7 × SC 13G/A, 1 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2021 · 70 filings — 51 × 4, 8 × SC 13G/A, 5 × 424B5 and 5 other forms
Counted, not listed; the year is on EDGAR.
2020 · 48 filings — 29 × 4, 7 × SC 13G/A, 3 × UPLOAD and 6 other forms
Counted, not listed; the year is on EDGAR.
2019 · 48 filings — 30 × 4, 6 × SC 13G/A, 3 × 3 and 8 other forms
Counted, not listed; the year is on EDGAR.
2018 · 41 filings — 23 × 4, 8 × SC 13G/A, 3 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2017 · 38 filings — 24 × 4, 6 × SC 13G/A, 2 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2016 · 35 filings — 24 × 4, 4 × SC 13G/A, 3 × CT ORDER and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 43 filings — 31 × 4, 5 × SC 13G/A, 2 × SC 13G and 5 other forms
Counted, not listed; the year is on EDGAR.
2014 · 43 filings — 26 × 4, 5 × 3, 4 × SC 13G and 5 other forms
Counted, not listed; the year is on EDGAR.
2013 · 46 filings — 32 × 4, 5 × SC 13G/A, 3 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2012 · 34 filings — 19 × 4, 5 × 3, 4 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2011 · 34 filings — 26 × 4, 4 × SC 13G, 2 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2010 · 15 filings — 6 × 4, 5 × 3, 2 × UPLOAD and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 18 filings — 16 × 4, 1 × 3, 1 × 5
Counted, not listed; the year is on EDGAR.
2008 · 15 filings — 12 × 4, 1 × 5, 1 × SC 13G and 1 other form
Counted, not listed; the year is on EDGAR.
2007 · 19 filings — 10 × 4, 2 × 3, 2 × 424B3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2006 · 19 filings — 5 × 4, 4 × SC 13G/A, 2 × 3 and 7 other forms
Counted, not listed; the year is on EDGAR.
2005 · 41 filings — 18 × 4, 4 × SC 13G, 3 × 5 and 12 other forms
Counted, not listed; the year is on EDGAR.
2004 · 15 filings — 6 × 4, 3 × 3, 2 × 5 and 3 other forms
Counted, not listed; the year is on EDGAR.
2003 · 25 filings — 19 × 4, 2 × SC 13G/A, 1 × 4/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 11 filings — 5 × SC 13G/A, 3 × 4, 1 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2001 · 7 filings — 4 × SC 13G, 2 × SC 13G/A, 1 × 8-A12G
Counted, not listed; the year is on EDGAR.
2000 · 20 filings — 4 × 425, 2 × S-4/A, 2 × S-8 and 11 other forms
Counted, not listed; the year is on EDGAR.
About this data#
Insmed Incorporated (INSM) has 1,823 filings on EDGAR going back to 2000: 37 annual reports, 86 quarterly reports and 364 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 19, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 29, 2026, covered results of operations. Over the last 13 months insiders sold $122.8M in 62 sales and bought nothing on the open market; 74 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Insmed Incorporated, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
Head-to-head:Compare with ALNY or any ticker →
FAQ#
- Where can I read INSM's latest 10-K?
- INSM's latest annual report, a 10-K, was filed on Feb 19, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did INSM last file an 8-K?
- On Oct 29, 2026 it covered results of operations. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Oct 29, 2026.
- Are INSM insiders buying or selling?
- Over the last 13 months insiders sold $122.8M in 62 sales and bought nothing on the open market; 74 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Brennan David R (Director) sold 25,000 shares on Sep 9, 2026 for $3.1M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has INSM made?
- 1,823 filings are on EDGAR under the registrant records that have been Insmed Incorporated, going back to 2000; 1,014 of them are insider ownership forms (Forms 3, 4, 5 and 144).